Synergy CHC Corp. (SNYR) Stock Competitors & Peer Comparison
See (SNYR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SNYR | $0.21 | +2.69% | 2.1M | -0.15 | -$1.40 | N/A |
| MCK | $805.96 | +1.66% | 94.3B | 20.58 | $39.15 | +0.41% |
| COR | $303.44 | +0.32% | 59B | 18.20 | $16.67 | +0.77% |
| CAH | $235.80 | +0.87% | 55.2B | 22.59 | $10.43 | +0.87% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $84.40 | +0.64% | 9.6B | 16.42 | $5.14 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| GRDN | $40.96 | -0.24% | 2.6B | 35.86 | $1.14 | N/A |
| PBH | $48.90 | +0.87% | 2.3B | 11.14 | $4.39 | N/A |
| ACH | $3.42 | +3.64% | 261.9M | 5.03 | $0.68 | N/A |
Stock Comparison
SNYR vs MCK Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, MCK has a market cap of 94.3B. Regarding current trading prices, SNYR is priced at $0.21, while MCK trades at $805.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas MCK's P/E ratio is 20.58. In terms of profitability, SNYR's ROE is +0.91%, compared to MCK's ROE of -2.65%. Regarding short-term risk, SNYR is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for SNYR.Check MCK's competition here
SNYR vs COR Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, COR has a market cap of 59B. Regarding current trading prices, SNYR is priced at $0.21, while COR trades at $303.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas COR's P/E ratio is 18.20. In terms of profitability, SNYR's ROE is +0.91%, compared to COR's ROE of +1.16%. Regarding short-term risk, SNYR is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for SNYR.Check COR's competition here
SNYR vs CAH Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, CAH has a market cap of 55.2B. Regarding current trading prices, SNYR is priced at $0.21, while CAH trades at $235.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas CAH's P/E ratio is 22.59. In terms of profitability, SNYR's ROE is +0.91%, compared to CAH's ROE of -0.56%. Regarding short-term risk, SNYR is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for SNYR.Check CAH's competition here
SNYR vs ABC Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, SNYR is priced at $0.21, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas ABC's P/E ratio is 21.92. In terms of profitability, SNYR's ROE is +0.91%, compared to ABC's ROE of +1.15%. Regarding short-term risk, SNYR is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for SNYR.Check ABC's competition here
SNYR vs HSIC Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, HSIC has a market cap of 9.6B. Regarding current trading prices, SNYR is priced at $0.21, while HSIC trades at $84.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas HSIC's P/E ratio is 16.42. In terms of profitability, SNYR's ROE is +0.91%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, SNYR is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for SNYR.Check HSIC's competition here
SNYR vs PDCO Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, SNYR is priced at $0.21, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas PDCO's P/E ratio is 20.48. In terms of profitability, SNYR's ROE is +0.91%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, SNYR is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for SNYR.Check PDCO's competition here
SNYR vs GRDN Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, GRDN has a market cap of 2.6B. Regarding current trading prices, SNYR is priced at $0.21, while GRDN trades at $40.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas GRDN's P/E ratio is 35.86. In terms of profitability, SNYR's ROE is +0.91%, compared to GRDN's ROE of +0.27%. Regarding short-term risk, SNYR is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for SNYR.Check GRDN's competition here
SNYR vs PBH Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, SNYR is priced at $0.21, while PBH trades at $48.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas PBH's P/E ratio is 11.14. In terms of profitability, SNYR's ROE is +0.91%, compared to PBH's ROE of +0.10%. Regarding short-term risk, SNYR is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for SNYR.Check PBH's competition here
SNYR vs ACH Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, ACH has a market cap of 261.9M. Regarding current trading prices, SNYR is priced at $0.21, while ACH trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas ACH's P/E ratio is 5.03. In terms of profitability, SNYR's ROE is +0.91%, compared to ACH's ROE of +2.65%. Regarding short-term risk, SNYR is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for SNYR.Check ACH's competition here
SNYR vs OMI Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, SNYR is priced at $0.21, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas OMI's P/E ratio is -0.47. In terms of profitability, SNYR's ROE is +0.91%, compared to OMI's ROE of +2.65%. Regarding short-term risk, SNYR is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for SNYR.Check OMI's competition here
SNYR vs HX Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, SNYR is priced at $0.21, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas HX's P/E ratio is -1.84. In terms of profitability, SNYR's ROE is +0.91%, compared to HX's ROE of -1.07%. Regarding short-term risk, SNYR is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for SNYR.Check HX's competition here
SNYR vs WGRX Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, WGRX has a market cap of 7.7M. Regarding current trading prices, SNYR is priced at $0.21, while WGRX trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas WGRX's P/E ratio is -0.29. In terms of profitability, SNYR's ROE is +0.91%, compared to WGRX's ROE of +15.45%. Regarding short-term risk, SNYR is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for SNYR.Check WGRX's competition here
SNYR vs ZYXI Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, SNYR is priced at $0.21, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, SNYR's ROE is +0.91%, compared to ZYXI's ROE of +11.38%. Regarding short-term risk, SNYR is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for SNYR.Check ZYXI's competition here
SNYR vs ZSTK Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, ZSTK has a market cap of 2.3M. Regarding current trading prices, SNYR is priced at $0.21, while ZSTK trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas ZSTK's P/E ratio is -0.04. In terms of profitability, SNYR's ROE is +0.91%, compared to ZSTK's ROE of -3.53%. Regarding short-term risk, SNYR is less volatile compared to ZSTK. This indicates potentially lower risk in terms of short-term price fluctuations for SNYR.Check ZSTK's competition here
SNYR vs RDGT Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, RDGT has a market cap of 1.4M. Regarding current trading prices, SNYR is priced at $0.21, while RDGT trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas RDGT's P/E ratio is -0.03. In terms of profitability, SNYR's ROE is +0.91%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, SNYR is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for SNYR.Check RDGT's competition here
SNYR vs CVET Comparison July 2026
SNYR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNYR stands at 2.1M. In comparison, CVET has a market cap of 0. Regarding current trading prices, SNYR is priced at $0.21, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNYR currently has a P/E ratio of -0.15, whereas CVET's P/E ratio is -69.97. In terms of profitability, SNYR's ROE is +0.91%, compared to CVET's ROE of -0.06%. Regarding short-term risk, SNYR is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for SNYR.Check CVET's competition here